<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DOBUTAMINE - dobutamine hydrochloride injection, solution </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First">R<span class="Sub">x</span> only</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Dobutamine Injection, USP is 1,2-benzenediol, 
4-[2-[[3-(4-hydro-xyphenyl)-1-methylpropyl]amino]ethyl]-hydrochloride, (±). It 
is a synthetic catecholamine.</p>
<p><img alt="image of chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a0882db1-2532-4b80-b753-68f013fe79e7&amp;name=chemical%20structure.jpg"></p>
<p>The clinical formulation is supplied in a sterile form for intravenous use 
only. Each mL contains: Dobutamine hydrochloride, equivalent to 12.5 mg (41.5 
µmol) dobutamine; 0.24 mg sodium metabisulfite (added during manufacture), and 
water for injection. pH adjusted between 2.5 to 5.5 with hydrochloric acid 
and/or sodium hydroxide. Dobutamine is oxygen sensitive.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Dobutamine is a direct-acting inotropic agent whose primary 
activity results from stimulation of the β receptors of the heart while 
producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and 
vasodilative effects. It does not cause the release of endogenous 
norepinephrine, as does dopamine. In animal studies, dobutamine produces less 
increase in heart rate and less decrease in peripheral <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> for a 
given inotropic effect than does isoproterenol.</p>
<p>In patients with depressed cardiac function, both dobutamine and 
isoproterenol increase the <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> to a similar degree. In the case of 
dobutamine, this increase is usually not accompanied by marked increases in 
heart rate (although <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> is occasionally observed), and the cardiac 
<span class="product-label-link" type="condition" conceptid="4231869" conceptname="Stroke volume">stroke volume</span> is usually increased. In contrast, isoproterenol increases the 
<span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span> primarily by increasing the heart rate while <span class="product-label-link" type="condition" conceptid="4231869" conceptname="Stroke volume">stroke volume</span> changes 
little or declines.</p>
<p>Facilitation of atrioventricular conduction has been observed in human 
electrophysiologic studies and in patients with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>.</p>
<p>Systemic <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> is usually decreased with administration of 
dobutamine. Occasionally, minimum <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> has been observed.</p>
<p>Most clinical experience with dobutamine is <span class="Underline">short-term</span>-not more than several hours in duration. In 
the limited number of patients who were studied for 24, 48, and 72 hours, a 
persistent increase in <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> occurred in some, whereas output returned 
toward baseline values in others.</p>
<p>The onset of action of dobutamine is within 1 to 2 minutes; however, as much 
as 10 minutes may be required to obtain the peak effect of a particular infusion 
rate.</p>
<p>The plasma half-life of dobutamine in humans is 2 minutes. The principal 
routes of metabolism are methylation of the catechol and conjugation. In human 
urine, the major excretion products are the conjugates of dobutamine and 
3-O-methyl dobutamine. The 3-O-methyl derivative of dobutamine is inactive.</p>
<p>Alteration of synaptic concentrations of catecholamines with either reserpine 
or tricyclic antidepressants does not alter the actions of dobutamine in 
animals, which indicates that the actions of dobutamine are not dependent on 
presynaptic mechanisms.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Dobutamine injection is indicated when parenteral therapy is 
necessary for inotropic support in the <span class="Underline">short-term</span> 
treatment of adults with cardiac decompensation due to depressed contractility 
resulting either from organic heart disease or from cardiac surgical 
procedures.</p>
<p>In patients who have <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> with rapid ventricular response, a 
digitalis preparation should be used prior to institution of therapy with 
dobutamine hydrochloride.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Dobutamine hydrochloride is contraindicated in patients with 
<span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">idiopathic hypertrophic subaortic stenosis</span> and in patients who have shown 
previous manifestations of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to dobutamine injection.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<ol>
<li>
<p class="First">Increase in Heart Rate or Blood Pressure</p>
<p>Dobutamine may cause a marked increase in heart rate or blood pressure, 
especially systolic pressure. Approximately 10% of patients in clinical studies 
have had rate increases of 30 beats/minute or more, and about 7.5% have had a 50 
mm Hg or greater increase in systolic pressure. Usually, reduction of dosage 
promptly reverses these effects. Because dobutamine facilitates atrioventricular 
conduction, patients with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> are at risk of developing rapid 
ventricular response. Patients with preexisting <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> appear to face an 
increased risk of developing an exaggerated pressor response.</p>
</li>
<li>
<p class="First">Ectopic Activity</p>
<p>Dobutamine may precipitate or exacerbate ventricular ectopic activity, but it 
rarely has caused <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>.</p>
</li>
<li>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></p>
<p>Reactions suggestive of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> associated with administration of 
dobutamine injection, including <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, and 
<span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, have been reported occasionally.</p>
</li>
<li><p class="First">Dobutamine injection contains sodium metabisulfite, a sulfite 
that may cause allergic-type reactions, including anaphylactic symptoms and 
life-threatening or less severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> episodes, in certain susceptible 
people. The overall prevalence of sulfite sensitivity in the general population 
is unknown and probably low. Sulfite sensitivity is seen more frequently in 
<span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatic</span> than in nonasthmatic people.</p></li>
</ol>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<a href="http://"></a>General<ol>
<li><p class="First">During the administration of dobutamine injection, as with any 
adrenergic agent, ECG and blood pressure should be continuously monitored. In 
addition, pulmonary wedge pressure and <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> should be monitored 
whenever possible to aid in the safe and effective infusion of dobutamine 
hydrochloride.</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">Hypovolemia</span> should be corrected with suitable volume expanders 
before treatment with dobutamine is instituted.</p></li>
<li><p class="First">No improvement may be observed in the presence of marked 
mechanical obstruction, such as severe valvular <span class="product-label-link" type="condition" conceptid="4189343" conceptname="Aortic valve stenosis">aortic stenosis</span>.</p></li>
</ol>
<p class="First"><span>Usage Following Acute Myocardial 
<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">Infarction</span></span>— Clinical experience with dobutamine injection following 
<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> has been insufficient to establish the safety of the drug 
for this use. There is concern that any agent that increases contractile force 
and heart rate may increase the size of an <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> by intensifying <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, 
but it is not known whether dobutamine does so.</p>
<a href="http://"></a><a href="http://"></a>Laboratory Tests<p>Dobutamine, like other β<span class="Sub">2</span>- agonists, can 
produce a mild reduction in serum potassium concentration, rarely to hypokalemic 
levels. Accordingly, consideration should be given to monitoring serum 
potassium.</p>
<a href="http://"></a><a href="http://"></a>Drug Interactions<p>Animal studies indicate that dobutamine may be ineffective if the 
patient has recently received a β-blocking drug. In such a case, the peripheral 
<span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> may increase.</p>
<p>Preliminary studies indicate that the concomitant use of dobutamine and 
nitroprusside results in a higher <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and, usually, a lower pulmonary 
wedge pressure than when either drug is used alone.</p>
<p>There was no evidence of drug interactions in clinical studies in which 
dobutamine was administered concurrently with other drugs, including digitalis 
preparations, furosemide, spironolactone, lidocaine, nitroglycerin, isosorbide 
dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic 
acid, and acetaminophen.</p>
<a href="http://"></a><a href="http://"></a>Carcinogenesis, Mutagenesis, Impairment of 
Fertility<p>Studies to evaluate the carcinogenic or mutagenic potential of 
dobutamine hydrochloride, or its potential to affect fertility, have not been 
conducted.</p>
<a href="http://"></a><a href="http://"></a>Pregnancy<p><span>Teratogenic Effects-Pregnancy Category 
B</span>— Reproduction studies performed in rats at doses up to the normal human 
dose (10 mcg/kg/min for 24 h, total daily dose of 14.4 mg/kg) and in rabbits at 
doses up to 2 times the normal human dose have revealed no evidence of harm to 
the fetus due to dobutamine. There are, however, no adequate and well-controlled 
studies in pregnant women. Because animal reproduction studies are not always 
predictive of human response, this drug should be used during pregnancy only if 
clearly needed.</p>
<a href="http://"></a><a href="http://"></a>Labor and Delivery<p>The effect of dobutamine injection on labor and delivery is 
unknown.</p>
<a href="http://"></a><a href="http://"></a>Nursing Mothers<p>It is not known whether this drug is excreted in human milk. 
Because many drugs are excreted in human milk, caution should be exercised when 
dobutamine hydrochloride is administered to a nursing woman. If a mother 
requires dobutamine treatment, breast-feeding should be discontinued for the 
duration of the treatment.</p>
<a href="http://"></a><a href="http://"></a>Pediatric Use<p>The safety and effectiveness of dobutamine injection for use in 
pediatric patients have not been studied.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span>Increased Heart Rate, Blood Pressure, 
and Ventricular Ectopic Activity</span>— A 10- to 20-mm increase in systolic 
blood pressure and an increase in heart rate of 5 to 15 beats/minute have been 
noted in most patients (see <span class="Bold">WARNINGS</span> regarding 
exaggerated chronotropic and pressor effects). Approximately 5% of patients have 
had increased premature ventricular beats during infusions. These effects are 
dose related.</p>
<p><span><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span>— Precipitous decreases in blood 
pressure have occasionally been described in association with dobutamine 
therapy. Decreasing the dose or discontinuing the infusion typically results in 
rapid return of blood pressure to baseline values. In rare cases, however, 
intervention may be required and reversibility may not be immediate.</p>
<p><span>Reactions at Sites of Intravenous Infusion</span>— 
<span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">Phlebitis</span> has occasionally been reported. Local inflammatory changes have been 
described following inadvertent infiltration. Isolated cases of cutaneous 
<span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> (destruction of skin tissue) have been reported.</p>
<p><span>Miscellaneous Uncommon Effects</span>— The 
following adverse effects have been reported in 1% to 3% of patients: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, 
<span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">anginal pain</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">nonspecific chest pain</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, and shortness of 
breath.</p>
<p>Isolated cases of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> have been reported.</p>
<p>Administration of dobutamine, like other catecholamines, can produce a mild 
reduction in serum potassium concentration, rarely to hypokalemic levels (see 
PRECAUTIONS).</p>
<p><span>Longer-Term Safety</span>— Infusions of up to 72 
hours have revealed no adverse effects other than those seen with shorter 
infusions.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdoses</span> of dobutamine have been reported rarely. The following 
is provided to serve as a guide if such an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is encountered.</p>
<p><span>Signs and Symptoms</span>— Toxicity from 
dobutamine hydrochloride is usually due to excessive cardiac β-receptor 
stimulation. The duration of action of dobutamine hydrochloride is generally 
short (T<span class="Sub">½</span> = 2 minutes) because it is rapidly metabolized 
by catechol-0-methyltransferase. The symptoms of toxicity may include <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, 
<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, 
and anginal and <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">nonspecific chest pain</span>. The positive inotropic and chronotropic 
effects of dobutamine on the myocardium may cause <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, 
<span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachyarrhythmias</span>, <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span>, and <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span>. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> 
may result from vasodilation.</p>
<p><span>Treatment</span>— To obtain up-to-date information 
about the treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, a good resource is your certified Regional 
Poison Control Center. Telephone numbers of certified poison control centers are 
listed in the <span class="Italics">Physicians’ Desk Reference</span> (PDR). In 
managing overdosage, consider the possibility of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">multiple drug overdoses</span>, 
interaction among drugs, and unusual drug kinetics in your patient.</p>
<p>The initial actions to be taken in a dobutamine hydrochloride <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are 
discontinuing administration, establishing an airway, and ensuring oxygenation 
and ventilation. Resuscitative measures should be initiated promptly. Severe 
<span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachyarrhythmias</span> may be successfully treated with propranolol or 
lidocaine. <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> usually responds to a reduction in dose or 
discontinuation of therapy.</p>
<p>Protect the patient’s airway and support ventilation and perfusion. If 
needed, meticulously monitor and maintain, within acceptable limits, the 
patient’s vital signs, blood gases, serum electrolytes, etc. If the product is 
ingested, unpredictable absorption may occur from the mouth and the 
gastrointestinal tract. Absorption of drugs from the gastrointestinal tract may 
be decreased by giving activated charcoal, which, in many cases, is more 
effective than emisis of lavage; consider charcoal instead of or in addition to 
gastric emptying. Repeated doses of charcoal over time may hasten elimination of 
some drugs that have been absorbed. Safeguard the patient’s airway when 
employing gastric emptying or charcoal.</p>
<p>Forced <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>, peritoneal dialysis, hemodialysis, or charcoal hemoperfusion 
have not been established as beneficial for an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of dobutamine 
hydrochloride.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span>Note</span>— Do not add dobutamine 
injection to 5% Sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> Injection or to any other strongly alkaline 
solution. Because of potential physical incompatibilities, it is recommended 
that dobutamine hydrochloride not be mixed with other drugs in the same 
solution. Dobutamine hydrochloride should not be used in conjunction with other 
agents or diluents containing both sodium bisulfite and ethanol.</p>
<p><span>Preparation and Stability</span>— At the time of 
administration, dobutamine injection must be further diluted in an IV container. 
Dilute 20 mL of dobutamine in at least 50 mL of diluent and dilute 40 mL of 
dobutamine in at least 100 mL of diluent. Use one of the following intravenous 
solutions as a diluent: Dextrose Injection 5%, Dextrose 5% and Sodium Chloride 
0.45% Injection, Dextrose 5% and Sodium Chloride 0.9% Injection, Dextrose 
Injection 10%, Isolyte<span class="Sup">®</span> M with 5% Dextrose Injection, 
Lactated Ringer’s Injection, 5% Dextrose in Lactated Ringer’s Injection, 
Normosol<span class="Sup">®</span>-M in D5-W, 20% Osmitrol<span class="Sup">®</span> 
in Water for Injection, Sodium Chloride Injection 0.9%, or Sodium Lactate 
Injection. Intravenous solutions should be used within 24 hours.</p>
<p><span>Recommended Dosage</span>— The rate of infusion 
needed to increase <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> usually ranged from 2.5 to 15 mcg/kg/min (see 
table). On rare occasions, infusion rates up to 40 mcg/kg/min have been required 
to obtain the desired effect.</p>
<a name="ia5dd261a-5fa8-4458-81aa-7415d490d426"></a><table width="70%"><tbody class="Headless">
<tr class="First"><td>
<span class="Bold">Dobutamine Injection</span><br>
</td></tr>
<tr class="Last"><td>
<span class="Bold">Rates of Infusion for Concentrations of 250, 500, and 1,000 mcg/mL</span><br>
</td></tr>
</tbody></table>
<a name="i37b685d0-38b8-43d4-8244-a606f9a8402f"></a><table width="70%"><tbody class="Headless">
<tr class="First">
<td>Drug Delivery Rate<br><br>(mcg/kg/min)<br>
</td>
<td>
<br>250 mcg/mL*<br>(mL/kg/min)<br>
</td>
<td>Infusion Delivery Rate<br>500 mcg/mL†<br>(mL/kg/min)<br>
</td>
<td>
<br>1,000 mcg/mL‡<br>(mL/kg/min)<br>
</td>
</tr>
<tr>
<td>2.5<br>
</td>
<td>0.01<br>
</td>
<td>0.005<br>
</td>
<td>0.0025<br>
</td>
</tr>
<tr>
<td>5<br>
</td>
<td>0.02<br>
</td>
<td>0.01<br>
</td>
<td>0.005<br>
</td>
</tr>
<tr>
<td>7.5<br>
</td>
<td>0.03<br>
</td>
<td>0.015<br>
</td>
<td>0.0075<br>
</td>
</tr>
<tr>
<td>10<br>
</td>
<td>0.04<br>
</td>
<td>0.02<br>
</td>
<td>0.01<br>
</td>
</tr>
<tr>
<td>12.5<br>
</td>
<td>0.05<br>
</td>
<td>0.025<br>
</td>
<td>0.0125<br>
</td>
</tr>
<tr class="Last">
<td>15<br>
</td>
<td>0.06<br>
</td>
<td>0.03<br>
</td>
<td>0.015<br>
</td>
</tr>
</tbody></table>*   250 mcg/mL of diluent<br>† 500 mcg/mL or 250 mg/500 mL of diluent<br>‡ 1,000 mcg/mL or 250 mg/250 mL of diluent<br>Rates of infusion in mL/h for Dobutamine Injection concentrations of 500 mcg/mL, 1000 
mcg/mL, and 2000 mcg/mL are given in Table 2.<br><br><br>                                                           Table 2<br>Dobutamine Injection Infustion Rate (mL/h) for 500 mcg/mL concentration<br>Drug Delivery Rate                        <span class="Underline">Patient Body Weight (kg)</span><span class="Underline"></span><a name="i8fb15eca-dc76-4ad2-8da9-c8b054082cd6"></a><table width="45%"><tbody class="Headless">
<tr class="First">
<td>mcg/kg/min)<br>
</td>
<td>30<br>
</td>
<td>40<br>
</td>
<td>50<br>
</td>
<td>60<br>
</td>
<td>70<br>
</td>
<td>80<br>
</td>
<td>90<br>
</td>
<td>100<br>
</td>
<td>110<br>
</td>
</tr>
<tr>
<td>2.5<br>
</td>
<td>9<br>
</td>
<td>12<br>
</td>
<td>15<br>
</td>
<td>18<br>
</td>
<td>21<br>
</td>
<td>24<br>
</td>
<td>27<br>
</td>
<td>30<br>
</td>
<td>33<br>
</td>
</tr>
<tr>
<td>5<br>
</td>
<td>18<br>
</td>
<td>24<br>
</td>
<td>30<br>
</td>
<td>36<br>
</td>
<td>42<br>
</td>
<td>48<br>
</td>
<td>54<br>
</td>
<td>60<br>
</td>
<td>66<br>
</td>
</tr>
<tr>
<td>7.5<br>
</td>
<td>27<br>
</td>
<td>36<br>
</td>
<td>45<br>
</td>
<td>54<br>
</td>
<td>63<br>
</td>
<td>72<br>
</td>
<td>81<br>
</td>
<td>90<br>
</td>
<td>99<br>
</td>
</tr>
<tr>
<td>10<br>
</td>
<td>36<br>
</td>
<td>48<br>
</td>
<td>60<br>
</td>
<td>72<br>
</td>
<td>84<br>
</td>
<td>96<br>
</td>
<td>108<br>
</td>
<td>120<br>
</td>
<td>132<br>
</td>
</tr>
<tr>
<td>12.5<br>
</td>
<td>45<br>
</td>
<td>60<br>
</td>
<td>75<br>
</td>
<td>90<br>
</td>
<td>105<br>
</td>
<td>120<br>
</td>
<td>135<br>
</td>
<td>150<br>
</td>
<td>165<br>
</td>
</tr>
<tr class="Last">
<td>15<br>
</td>
<td>54<br>
</td>
<td>72<br>
</td>
<td>90<br>
</td>
<td>108<br>
</td>
<td>126<br>
</td>
<td>144<br>
</td>
<td>162<br>
</td>
<td>180<br>
</td>
<td>198<br>
</td>
</tr>
</tbody></table>
<br>Dobutamine Injection Infustion Rate (mL/h) for 1,000 mcg/mL concentration<br>
Drug Delivery Rate                        <span class="Underline">Patient Body Weight (kg)</span><span class="Underline"></span><a name="ia0fc8fe6-1b88-4e78-8da0-e5a3ba2d4d97"></a><table width="45%"><tbody class="Headless">
<tr class="First">
<td>mcg/kg/min)<br>
</td>
<td>30<br>
</td>
<td>40<br>
</td>
<td>50<br>
</td>
<td>60<br>
</td>
<td>70<br>
</td>
<td>80<br>
</td>
<td>90<br>
</td>
<td>100<br>
</td>
<td>110<br>
</td>
</tr>
<tr>
<td>2.5<br>
</td>
<td>4.5<br>
</td>
<td>6<br>
</td>
<td>7.5<br>
</td>
<td>9<br>
</td>
<td>10.5<br>
</td>
<td>12<br>
</td>
<td>13.5<br>
</td>
<td>15<br>
</td>
<td>16.5<br>
</td>
</tr>
<tr>
<td>5<br>
</td>
<td>9<br>
</td>
<td>12<br>
</td>
<td>15<br>
</td>
<td>18<br>
</td>
<td>21<br>
</td>
<td>24<br>
</td>
<td>27<br>
</td>
<td>30<br>
</td>
<td>33<br>
</td>
</tr>
<tr>
<td>7.5<br>
</td>
<td>13.5<br>
</td>
<td>18<br>
</td>
<td>22.5<br>
</td>
<td>27<br>
</td>
<td>31.5<br>
</td>
<td>36<br>
</td>
<td>40.5<br>
</td>
<td>45<br>
</td>
<td>49.5<br>
</td>
</tr>
<tr>
<td>10<br>
</td>
<td>18<br>
</td>
<td>24<br>
</td>
<td>30<br>
</td>
<td>36<br>
</td>
<td>42<br>
</td>
<td>48<br>
</td>
<td>54<br>
</td>
<td>60<br>
</td>
<td>66<br>
</td>
</tr>
<tr>
<td>12.5<br>
</td>
<td>22.5<br>
</td>
<td>30<br>
</td>
<td>37.5<br>
</td>
<td>45<br>
</td>
<td>52.5<br>
</td>
<td>60<br>
</td>
<td>67.5<br>
</td>
<td>75<br>
</td>
<td>82.5<br>
</td>
</tr>
<tr class="Last">
<td>15<br>
</td>
<td>27<br>
</td>
<td>36<br>
</td>
<td>45<br>
</td>
<td>54<br>
</td>
<td>63<br>
</td>
<td>72<br>
</td>
<td>81<br>
</td>
<td>90<br>
</td>
<td>99<br>
</td>
</tr>
</tbody></table>
Dobutamine Injection Infustion Rate (mL/h) for 2,000 mcg/mL concentration<br>
Drug Delivery Rate                        <span class="Underline">Patient Body Weight (kg)</span><span class="Underline"></span><a name="if39ed194-bd25-4613-8047-942ecf1d7d69"></a><table width="45%"><tbody class="Headless">
<tr class="First">
<td>mcg/kg/min)<br>
</td>
<td>30<br>
</td>
<td>40<br>
</td>
<td>50<br>
</td>
<td>60<br>
</td>
<td>70<br>
</td>
<td>80<br>
</td>
<td>90<br>
</td>
<td>100<br>
</td>
<td>110<br>
</td>
</tr>
<tr>
<td>2.5<br>
</td>
<td>2<br>
</td>
<td>3<br>
</td>
<td>4<br>
</td>
<td>4.5<br>
</td>
<td>5<br>
</td>
<td>6<br>
</td>
<td>7<br>
</td>
<td>7.5<br>
</td>
<td>8<br>
</td>
</tr>
<tr>
<td>5<br>
</td>
<td>4.5<br>
</td>
<td>6<br>
</td>
<td>7.5<br>
</td>
<td>9<br>
</td>
<td>10.5<br>
</td>
<td>12<br>
</td>
<td>13.5<br>
</td>
<td>15<br>
</td>
<td>16.5<br>
</td>
</tr>
<tr>
<td>7.5<br>
</td>
<td>7<br>
</td>
<td>9<br>
</td>
<td>11<br>
</td>
<td>13.5<br>
</td>
<td>16<br>
</td>
<td>18<br>
</td>
<td>20<br>
</td>
<td>22.5<br>
</td>
<td>25<br>
</td>
</tr>
<tr>
<td>10<br>
</td>
<td>9<br>
</td>
<td>12<br>
</td>
<td>15<br>
</td>
<td>18<br>
</td>
<td>21<br>
</td>
<td>24<br>
</td>
<td>27<br>
</td>
<td>30<br>
</td>
<td>33<br>
</td>
</tr>
<tr>
<td>12.5<br>
</td>
<td>11<br>
</td>
<td>15<br>
</td>
<td>19<br>
</td>
<td>22.5<br>
</td>
<td>26<br>
</td>
<td>30<br>
</td>
<td>34<br>
</td>
<td>37.5<br>
</td>
<td>41<br>
</td>
</tr>
<tr class="Last">
<td>15<br>
</td>
<td>13.5<br>
</td>
<td>18<br>
</td>
<td>22.5<br>
</td>
<td>27<br>
</td>
<td>31.5<br>
</td>
<td>36<br>
</td>
<td>40.5<br>
</td>
<td>45<br>
</td>
<td>49.5<br>
</td>
</tr>
</tbody></table>
<br>The rate of administration and the duration of therapy should be adjusted 
according to the patient’s response as determined by heart rate, presence of 
ectopic activity, blood pressure, urine flow, and, whenever possible, 
measurement of central venous or pulmonary wedge pressure and cardiac 
output.<p>Concentrations of up to 5,000 mcg/mL have been administered to humans (250 
mg/50 mL). The final volume administered should be determined by the fluid 
requirements of the patient.</p>
<p>Parenteral drug products should be inspected visually for particulate matter 
and discoloration prior to administration, whenever solution and container 
permit.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Dobutamine Injection, USP, 12.5 mg/mL is available as:</p>
<p>20 mL Single-Dose Vials containing 250 mg dobutamine (as the hydrochloride),   NDC 54868-5717-0<br></p>
<p>20 mL Single-Dose Vials containing 250 mg dobutamine (as the hydrochloride), 
boxes of 10,   NDC 54868-5717-2<br></p>
<p>40 mL Single-Dose Vials containing 500 mg dobutamine (as the hydrochloride), 
boxes of 10,   NDC 54868-5717-1<br></p>
<p><br></p>
<p>Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]</p>
<p>October, 2004.</p>
<a name="i9c7e0e65-eb43-493b-8be2-dfca016c2ebc"></a><table width="30%"><tbody class="Headless">
<tr class="First">
<td>Printed in USA<br>
</td>
<td><p class="First">©Hospira 2004   EN-0623<br></p></td>
</tr>
<tr class="Last">
<td>Hospira, Inc., Lake Forest, IL   60045 USA<br>
</td>
<td><br></td>
</tr>
</tbody></table>
<br><span class="Bold">Relabeling of "Additional" barcode label by:<br></span>Physicians Total Care, Inc.<br>Tulsa, OK      74146<br>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>Dobutamine Injection, USP, 12.5 mg/mL<br><br>20 mL<br><div class="Figure"><img alt="image of 20 mL package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a0882db1-2532-4b80-b753-68f013fe79e7&amp;name=5717-0.jpg"></div>
<br>40 mL<br><div class="Figure"><img alt="image of 40 mL package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a0882db1-2532-4b80-b753-68f013fe79e7&amp;name=5717-1.jpg"></div>
<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DOBUTAMINE 		
					</strong><br><span class="contentTableReg">dobutamine hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5717(NDC:0409-2025)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DOBUTAMINE HYDROCHLORIDE</strong> (DOBUTAMINE) </td>
<td class="formItem">DOBUTAMINE HYDROCHLORIDE</td>
<td class="formItem">12.5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM METABISULFITE</strong></td>
<td class="formItem">0.24 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5717-0</td>
<td class="formItem">1  in 1 BOX, UNIT-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">20 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-5717-2</td>
<td class="formItem">10  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">20 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-5717-1</td>
<td class="formItem">10  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem"></td>
<td class="formItem">40 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA074292</td>
<td class="formItem">12/11/2006</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ecd0523c-6fef-4437-90af-23719e7aaf40</div>
<div>Set id: a0882db1-2532-4b80-b753-68f013fe79e7</div>
<div>Version: 1</div>
<div>Effective Time: 20110125</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
